Medical Management of Benign Prostatic Hyperplasia
 March 2024   
in “
 Cleveland Clinic journal of medicine 
”
 
      
   TLDR  Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.   
  Medical management of benign prostatic hyperplasia (BPH) has advanced, with alpha-blockers and 5-alpha reductase inhibitors remaining primary treatments. New evidence supports the use of phosphodiesterase-5 inhibitors and beta-3 agonists for additional symptom relief. This review focuses on the indications, benefits, and side effects of these pharmacotherapies, while surgical treatments are discussed elsewhere.